TuHURA Biosciences (HURA) to Release Earnings on Wednesday

TuHURA Biosciences (NASDAQ:HURA) is anticipated to announce its earnings results before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter.

TuHURA Biosciences Trading Up 3.8 %

Shares of HURA opened at $3.30 on Friday. The company’s fifty day simple moving average is $4.41. TuHURA Biosciences has a one year low of $2.84 and a one year high of $14.60.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. RODMAN&RENSHAW raised shares of TuHURA Biosciences to a “strong-buy” rating in a research note on Thursday, December 19th. Maxim Group initiated coverage on TuHURA Biosciences in a report on Tuesday, November 5th. They issued a “buy” rating and a $15.00 target price for the company. Finally, Rodman & Renshaw initiated coverage on shares of TuHURA Biosciences in a report on Thursday, December 19th. They set a “buy” rating and a $11.00 price target for the company.

Hedge Funds Weigh In On TuHURA Biosciences

An institutional investor recently bought a new position in TuHURA Biosciences stock. Bank of America Corp DE purchased a new stake in shares of TuHURA Biosciences (NASDAQ:HURA) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 14,314 shares of the company’s stock, valued at approximately $59,000. Institutional investors and hedge funds own 0.62% of the company’s stock.

About TuHURA Biosciences

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.